Calgary begins adding fluoride to drinking water for first time in almost 15 years
The city, in a news release, says it has begun adding the chemical into the water at the direction of councillors.
Council's decision follows a 2021 plebiscite in which about two-thirds of those who voted said they wanted fluoride put back in the water.
The city says fluoride is safe at low levels and is an effective way to prevent cavities and keep teeth strong.
Fluoride has been a contentious health issue with municipalities, and in Calgary, the water was fluoridated for 20 years until council directed it to be halted in 2011.
Edmonton, Red Deer and other Alberta municipalities already add fluoride to drinking water.
The change comes at a price, as the city says it will cost $28 million to upgrade its two water treatment plants for the fluoride.
Fluoride will cost $1 million more per year for operating and maintenance, and will be paid for through water rates.
This report by The Canadian Press was first published June 30, 2025.
The Canadian Press
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
CIBC Foundation and TELUS Friendly Future Foundation announce landmark $2 million partnership
New partnership strengthens commitment to nationwide educational access, creating more pathways for students facing barriers TORONTO, July 2, 2025 /CNW/ - The CIBC Foundation and the TELUS Friendly Future Foundation announced a transformative $2 million partnership to launch the TELUS Momentum Student Bursary, powered by CIBC Foundation. With each Foundation contributing $1 million, this multi-year partnership will fuel momentum for up to 500 young changemakers from the Black community, helping them accelerate their ambitions and impact across the globe. "This innovative partnership unites two leading Canadian Foundations with a shared vision to expand educational and leadership opportunities for our youth," said Darren Entwistle, President and CEO, TELUS. "Today's landmark funding commitment by the TELUS Friendly Future Foundation and CIBC Foundation will enable us to further expand our TELUS Student Bursary program, equipping the next generation of leaders with the essential tools to realize their dream of post-secondary education while also effecting meaningful change within their communities. Together, we are paving the way for a more inclusive and dynamic workforce in Canada, and creating a friendlier future for all Canadians." "The launch of the TELUS Momentum Student Bursary, powered by CIBC Foundation is a testament to both Foundations' continued efforts in ensuring that our next generation of leaders have access to a brighter, more inclusive future," said Victor Dodig, President and CEO, CIBC. "The bursary will generate momentum for their ambitions to flourish and help them address some of society's most pressing issues. Together, this new partnership helps us do even more to create a world where everyone has the opportunity to realize their ambitions." The TELUS Momentum Student Bursary, powered by CIBC Foundation, will unlock access to education and career pathways for young Black leaders, whose talents and community leadership are critical for helping solve pressing social issues. Bursaries are awarded to students who are facing financial barriers and are committed to making a difference in their communities. Recipients will also benefit from comprehensive support, including TELUS' Mobility for Good and Internet for Good programs, access to the CIBC Best Student Life Bundle and CIBC Smart Planner, which can help create healthier financial habits, free mental health support from TELUS Health, as well as career learning opportunities enabled by TELUS. "The support from CIBC Foundation and TELUS Friendly Future Foundation has given me the opportunity to focus on my studies and get involved in community work that I'm passionate about," said Kay Palmer, recipient of the TELUS Momentum Student Bursary, powered by CIBC Foundation. "My dream is to work in forensic psychology, and this support is helping me become the change I want to see. Together, we'll keep this momentum going and build a more inclusive tomorrow." Since the launch of the TELUS Student Bursary in 2023, the TELUS Friendly Future Foundation has already provided bursaries to more than 1000 students across nine provinces and 93 different schools, with more than 50 percent awarded to first-generation post-secondary students. With applications already received for the 2025/26 academic year, this partnership with CIBC Foundation will enable more students to receive bursary support starting Fall 2025. For more information about the TELUS Student Bursary program and how you can support the next generation of Canadian leaders, visit About CIBC Foundation CIBC is a leading North American financial institution with 14 million personal banking, business, public sector and institutional clients. The CIBC Foundation serves our commitment to creating a world without limits to ambition by championing inclusive communities, investing in financial education and supporting cancer research, treatment, education and support programs through corporate donations and community partnerships. Learn more about our community impact. Ongoing news releases and more information about CIBC can be found at About TELUS Friendly Future Foundation TELUS Friendly Future Foundation is a Canadian registered charity that believes all youth, regardless of circumstance, deserve an equal opportunity to reach their full potential. By funding more than 500 charities each year that provide education and health programs, many enabled by technology, along with providing educational bursaries, TELUS Friendly Future Foundation is helping youth across Canada build skills, confidence and feel a sense of belonging. In 2024 alone, we provided more than $11 million in grants to 500+ charitable programs across Canada, and over $2 million in bursaries to 500+ post-secondary students in financial need who are committed to making a difference in their communities. About TELUS TELUS (TSX: T, NYSE: TU) is a world-leading communications technology company operating in more than 45 countries and generating over $20 billion in annual revenue with more than 20 million customer connections through our advanced suite of broadband services for consumers, businesses and the public sector. We are committed to leveraging our technology to enable remarkable human outcomes. TELUS is passionate about putting our customers and communities first, leading the way globally in client service excellence and social capitalism. Our TELUS Health business is enhancing more than 150 million lives across 200 countries and territories through innovative preventive medicine and well-being technologies. Our TELUS Agriculture & Consumer Goods business utilizes digital technologies and data insights to optimize the connection between producers and consumers. Guided by our enduring 'give where we live' philosophy, TELUS, our team members and retirees have contributed $1.8 billion in cash, in-kind contributions, time and programs including 2.4 million days of service since 2000, earning us the distinction of the world's most giving company. For more information, visit or follow @TELUSNews on X and @Darren_Entwistle on Instagram. For media inquiries, please contact: Saara Rahikka TELUS Public Relations SOURCE TELUS Friendly Future Foundation View original content to download multimedia: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Medscape
2 hours ago
- Medscape
Exercise Intervention Boosts Colon Cancer Survival Benefits
This transcript has been edited for clarity. Hello, everyone. I'm Dr Bishal Gyawali, associate professor of oncology at Queens University, Kingston, Canada. I'm very happy to share with you some of the most exciting data that I just saw at the plenary session at ASCO 2025. Before that, I'm going to talk to you about a fantastic new drug called exercisumab. I'm joking, of course. Exercise has been shown to improve the lives of patients with colon cancer. I'm joking that if there were a drug called exercisumab, the data would be so compelling that we'd all want to use it and fund it today. Because this is not a drug and it's about exercise, I see some challenges in implementation. I hope that I'm able to convince you that the data are really compelling and we should make an effort so that our health systems will integrate this as a part of cancer care for patients with high-risk stage II and stage III colon cancer who receive adjuvant chemotherapy. The trial I'm talking about is called the CHALLENGE trial, which was not presented at the plenary but should have been. In this trial, patients who had high-risk stage II and stage III colon cancer, after they completed their adjuvant chemotherapy, were randomized to receive a structured exercise program vs the standard-of-care arm. The standard-of-care arm patients received health education but did not receive a structured exercise program. The goal of the structured exercise program was to improve physical activity by at least 10 MET-hours compared to the baseline of these patients. The primary endpoint was disease-free survival. Disease-free survival was significantly improved, and overall survival was also significantly improved. The 5-year disease-free survival rates improved by almost 7%, and the 8-year overall survival rates also improved by a similar amount. The hazard ratio for disease-free survival was 0.72, and the hazard ratio for overall survival was 0.63. These are very compelling results. If you compare these results with results from other trials, you'll see that this is a no-brainer. If this were a drug, you would want to use it today. There are some nuances about this trial that I want to highlight. When we talk about the results, some of the comments were, 'Oh yes, I have been asking my patients to exercise anyway.' Exercise improves quality of life, it'll reduce weight, and these are all known to benefit patients. I have been telling my patients to exercise, but this trial is not about telling patients to exercise. This trial is about having a formal, structured exercise program. There are particular details. Patients need to have an in-person visit with a therapist every 2 weeks for the first year and then every month for the next 2 years, so it's a 3-year therapy program. It's a scientifically designed and tailored program. It's not just saying, oh, you should exercise. In fact, saying you should exercise and giving some health education was the control arm of this treatment, not the interventional arm. The control arm patients were told about this trial, the potential benefits of the exercise, why they should enroll in this trial, and they were given health education materials. An interesting observation is that even the control arm patients had improvements in their physical functioning, VO 2 , and all those parameters from baseline to subsequent visits. One limitation is the adherence rate to exercise. We see that the adherence rate kept falling with time. I think that by the end of 3 years, the adherence rate to the exercise program was around 60%-65% in that ballpark, which is a limitation. Having said that, the analysis accounts for all of that. Despite that limitation, we are seeing this substantial benefit. If you want to compare that with the ATOMIC trial, which was a plenary presentation of immunotherapy plus FOLFOX for patients who needed adjuvant FOLFOX in stage III colon cancer patients, of course, the addition of atezolizumab to FOLFOX improved disease-free survival rates. The primary endpoint here was 3-year disease-free survival, and it improved significantly. It was a plenary, and people were making the argument that this should immediately change practice. If you compare that with this exercise trial that I just discussed: A, think about the added toxicities; B, think about the added cost; and C, think about how feasible it is to implement. I think it's a no-brainer that we need to start having health systems funds for a structured exercise program for our patients with colon cancer. Yes, the atezolizumab data and the ATOMIC trial data look very interesting and this is one of the first advances in treatment of adjuvant colon cancer in a long time. This is for patients with microsatellite instability-high status. We don't have overall survival results yet. Disease-free survival is a much more reliable predictor of overall survival in this particular setting. I believe that overall survival might be positive, but we also need to know what percentage of these patients got immunotherapy when they relapsed, because immunotherapy is already standard of care for these patients when they relapse. The other point about this trial is, do they all actually need 1 year of atezolizumab? Probably not. As the discussant highlighted in her talk, in many settings, we are now using neoadjuvant strategies. Using two or three cycles might be enough. The broader point that I'm trying to make is contrasting these two studies and inviting you to think about how different these are, even in terms of magnitude of benefit. The exercise trial has overall survival, not just disease-free survival, at an 8-year time point. When I asked Dr Booth about the cost of this intervention, he said for the whole 3-year time point, it might be around $3000 Canadian dollars. This trial was conducted mostly in Canada and in Australia. As opposed to atezolizumab, where a month of atezolizumab alone is going to cost $15,000, so that's just a perspective I wanted to put forward. One more thing I wanted to talk about today is the SERENA-6 trial, which was discussed at the plenary session. This is a trial for patients with estrogen receptor-positive, HER2-negative metastatic breast cancer who have been on a CDK4/6 inhibitor plus aromatase inhibitor for 6 months. They were then tested with ctDNA to detect ESR1 mutations early, and if this was detected, then they were randomized to either follow the same treatment, which is the control arm, or get the new drug. The primary endpoint here was progression-free survival. This was debated often during the season. We have so many debates about progression-free and overall survival, but for this particular trial, progression-free survival makes no sense because this is just detecting relapse early. Detecting relapse early does not always mean that you need to intervene early. Of course, if you are intervening early, then you are going to prolong time to tumor progression. The progression-free survival in this sense is more like time on treatment with this drug rather than true progression-free survival. You're just changing treatment early, and the control arm patients are not getting that treatment when they progress. Measuring progression-free survival alone here felt similar to measuring CA-125, or whatever tumor markers we measure, then instituting treatment early and claiming that patients have a longer time on treatment, when in fact, it's just lead time bias or intervening early without knowing that it's going to improve outcomes. A final trial from the plenary session was the MATTERHORN trial. I want to bring that up as well because this trial was investigating durvalumab plus perioperative FLOT in patients with esophageal cancers. This trial had a significant improvement in event-free survival, but has not improved overall survival yet. It may or may not translate into an overall survival improvement. The discussant did not cover the limitations of this trial well, and that's why I wanted to bring it up. There are several factors to consider here. There are other trials in similar settings, where event-free or disease-free survival have improved, but overall survival has not. There is no point in getting super excited about this because it may not translate to overall survival, just like other immunotherapy trials in this space. The other thing is, we need to make sure what treatments patients are getting at the time of progression or at the time of relapse. Are they getting the right treatment?If they're not getting the right treatment, then any survival difference can be simply a function of the control arm patients not getting the right treatment at the time of relapse. If we compare these results with results of other immunotherapy trials, I don't think the results are substantially different. Yes, an event-free survival improvement is important, but especially in this setting, in this disease, we have seen other trials where disease-free or event-free survival have not necessarily led to an overall survival improvement. We need to be asking ourselves, can we claim that it is already practice changing without having those results? I don't think that's the case. Those are some of my thoughts from this year's plenary session at ASCO 2025. Thank you.
Forbes
2 hours ago
- Forbes
UnitedHealth: Buy Or Sell UNH Stock At $325?
CANADA - 2025/04/06: In this photo illustration, the UnitedHealth Group logo is seen displayed on a ... More smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images) UnitedHealth's stock (NYSE:UNH) has undergone a noticeable decline, decreasing from a peak of around $600 in April to about $275 in May, and then making a slight recovery to $325. This drop followed the company's announcement of disappointing Q1 results, the later retraction of its earnings forecast, and sudden shifts in top management. While these occurrences have naturally raised concerns regarding UNH stock, it is also trading at very appealing valuations. Additionally, as outlined below, the company exhibits robust operating performance and financial health across key metrics such as Growth, Profitability, Financial Stability, and Downturn Resilience. Nevertheless, for those investors who prefer less volatility than individual stocks, the Trefis High Quality portfolio offers an alternative — having surpassed the S&P 500 and delivered returns greater than 91% since its inception. Separately, see – SOFI Stock To $30? How Does UnitedHealth's Valuation Look vs. The S&P 500? When considering what you pay per dollar of sales or profit, UNH stock appears inexpensive in relation to the broader market. How Have UnitedHealth's Revenues Grown Over Recent Years? UnitedHealth's Revenues have exhibited significant growth in recent years. How Profitable Is UnitedHealth? UnitedHealth's profit margins are significantly lower than those of most companies covered by Trefis. Does UnitedHealth Look Financially Stable? UnitedHealth's balance sheet appears robust. How Resilient Is UNH Stock During A Downturn? UNH stock has proven to be more resilient than the benchmark S&P 500 index during some recent downturns. As investors speculate on the possibility of a soft landing in the U.S. economy, how serious could it get if another recession strikes? Our dashboard How Low Can Stocks Go During A Market Crash shows how significant stocks fared during and after previous market crashes. Putting All The Pieces Together: What It Means For UNH Stock In conclusion, UnitedHealth's performance regarding the outlined metrics is as follows: UnitedHealth has shown strong performance across the previously mentioned parameters. This, in conjunction with its current low valuation, renders the stock appealing and reinforces our finding that UNH represents a worthwhile buying opportunity. Of course, there's always a level of uncertainty. In light of the recent challenges, including Centene's latest withdrawal of guidance, investors may be cautious about selecting UNH. However, for long-term investors, the presently discounted valuation is likely advantageous, especially given the company's consistent history of strong performance. While UNH stock appears promising, investing in a single stock can carry risks. Conversely, the Trefis High Quality (HQ) Portfolio, comprising 30 stocks, has a history of comfortably outperforming the S&P 500 over the last 4-year period. What accounts for this? Collectively, HQ Portfolio stocks produced superior returns with lower risk compared to the benchmark index; providing a less turbulent experience, as demonstrated by HQ Portfolio performance metrics.
